Table 3

The characteristics of the patients with hypertensive encephalopathy (N = 5)
Case 1 Case 2 Case 3 Case 4 Case 5
Gender (F/M) M M M M M
Age (year) 9 12 13 5 14
Weight (kg) 24 39 68 19 35
Height (cm) 134 158 110
Family history no no no no no
Arrival BP 166/130 176/86 220/128 231/172 148/109
Hypertension stage stage 2 stage 2 stage 2 stage 2 stage 2
SBP > 99th percentile + 5 33(25.3%) 42(31.4%) 82(59.4%) 106(84.8%) 3(2%)
DBP > 99th percentile + 5 38(41.3%) 34(36.1%) 86(101%) 12(11%)
clinical manifestations
 Consciousness change Coma Coma Coma Drowsy Disturbance
 Headache + 0 + + +
 Nausea/Vomiting 0 0 + + +
 Visual symptoms 0 0 + 0 0
 Seizure 0 0 0 + +
 Dizzy 0 0 0 0 +
 Chest tightness 0 0 0 0 0
Drug for anti-HTN Labetalol, Furosemide Labetalol Nifedipine, Labetalol Nifedipine captopril / amlodipine
Underlying causes oncology Pheochromocytoma 0 0 oncology Paraganglioneuroma Renal disease
Recurrent episode (times) 0 0 0 3 >5
CSF data 0 0 0 0 normal
EEG finding 0 0 normal 0 normal
Hospitalization duration (days) (ward/ICU/POU) 9(4/5/0) 11(5/6/0) 5(3/2/0) 7(7/0/0) 6(6/0/0)

SBP: systolic blood pressure; DBP: diastolic blood pressure; HTN: hypertension; CSF: cerebrospinal fluid; EEG: Electroencephalography; ICU: intensive care unit; POU: pediatric observation unit.

Yang et al.

Yang et al. BMC Pediatrics 2012 12:200   doi:10.1186/1471-2431-12-200

Open Data